Key result
The CHA2DS2-VASc score did not significantly predict the presence of cerebral microbleeds (OR 1.389) in geriatric stroke patients with atrial fibrillation.
Why the study?
It was unknown whether the CHA2DS2-VASc score and left atrial diameter could predict cerebral small vessel disease in patients older than 65 years with AF-related ischemic stroke.
Do the CHA2DS2-VASc score and left atrial diameter predict the presence of cerebral small vessel disease in geriatric patients with atrial fibrillation and ischemic stroke?
Observational (n=60)
Single-blind
No
Do the CHA2DS2-VASc score and left atrial diameter predict the presence of cerebral small vessel disease in geriatric patients with atrial fibrillation and ischemic stroke?
Odds Ratio: 1.389 (95% CI 0.961–2.008)
p-value: p=0.08
The CHA2DS2-VASc score and left atrial diameter do not broadly predict cerebral microbleeds in geriatric AF patients with stroke, though they may have predictive value in specific subgroups like those with diabetes or coronary artery disease.
CHA2DS2-VASc score may not identify microbleed risk in geriatric AF stroke; leaves open alternative predictors for clinical use.
Objective The objective of this study was to determine whether the CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke, vascular disease, age, sex) score and left atrial diameter (LAD) could predict the presence of cerebral small vessel disease (cSVD) in patients older than 65 years with atrial fibrillation as the cause of ischemic stroke. Materials and methods In this study, we included patients over 65 years of age who had suffered an ischemic stroke caused by atrial fibrillation within 30 days after the onset of symptoms. The data recorded included demographics, electrocardiograms, Holter monitors, and echocardiography reports. The anteroposterior LAD, determined by transthoracic echocardiography, was analyzed. Each patient's CHA2DS2-VASc score was calculated. Brain magnetic resonance imaging (MRI) assessed white matter hyperintensities (WMH) on fluid-attenuated inversion recovery (FLAIR) images and cerebral microbleeds (CMBs) on susceptibility-weighted sequences. The Fazekas score, based on WMH on MRI, was used to grade the severity of gliosis. Participants were categorized into three groups according to their quantitative CMB burden. Findings The study included 60 participants, with a mean age of 80 years (range 65-99), and 43.3% (n = 26) were male. The CHA2DS2-VASc score had a mean value of 4.21 (range 2-8), and the mean LAD was 4.17 (range 2.6-5.3) cm. The CHA2DS2-VASc score did not predict CMBs (OR, 1.389; 95% CI, 0.961-2.008, p = 0.08) in geriatric stroke patients with atrial fibrillation. However, in the subgroup of patients with diabetes mellitus, the CHA2DS2-VASc score was higher in those with CMB 1-4 and CMB ≥ 5 than in those without CMB. Additionally, the risk of CMBs 1-4 increased with higher LAD compared to patients without LAD. Conclusion The LAD and CHA2DS2-VASc scores were not significantly associated with CMB prediction in elderly stroke patients with atrial fibrillation. In a diabetes mellitus subgroup, the CHA2DS2-VASc score was indicative of CMB. An increased LAD elevates the risk of CMBs in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Tanburoğlu et al. (2023) conducted an observational in Atrial fibrillation and ischemic stroke or TIA (n=60). CHA2DS2-VASc score and Left Atrial Diameter was evaluated on Presence of cerebral microbleeds (CMBs ≥ 1 vs 0) (OR 1.389, 95% CI 0.961-2.008, p=0.08). The CHA2DS2-VASc score did not significantly predict the presence of cerebral microbleeds (OR 1.389) in geriatric stroke patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: